Chinook Therapeutics Statistics Share Statistics Chinook Therapeutics has 67.05M
shares outstanding. The number of shares has increased by 43.31%
in one year.
Shares Outstanding 67.05M Shares Change (YoY) 43.31% Shares Change (QoQ) 3.79% Owned by Institutions (%) n/a Shares Floating 61.16M Failed to Deliver (FTD) Shares 2,992 FTD / Avg. Volume 0.15%
Short Selling Information The latest short interest is 2.88M, so 4.01% of the outstanding
shares have been sold short.
Short Interest 2.88M Short % of Shares Out 4.01% Short % of Float 4.59% Short Ratio (days to cover) 3.45
Valuation Ratios The PE ratio is -9.14 and the forward
PE ratio is null.
Chinook Therapeutics's PEG ratio is
-0.31.
PE Ratio -9.14 Forward PE n/a PS Ratio 275.21 Forward PS n/a PB Ratio 3.82 P/FCF Ratio -14.16 PEG Ratio -0.31
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Chinook Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.59,
with a Debt / Equity ratio of 0.09.
Current Ratio 7.59 Quick Ratio 7.59 Debt / Equity 0.09 Debt / EBITDA -0.24 Debt / FCF -0.33 Interest Coverage -25.78
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $28.64K Profits Per Employee $-862.69K Employee Count 214 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax 4.34M Effective Tax Rate -2.41%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 0.67, so Chinook Therapeutics's
price volatility has been higher than the market average.
Beta 0.67 52-Week Price Change n/a 50-Day Moving Average 38.59 200-Day Moving Average 26.93 Relative Strength Index (RSI) 78.49 Average Volume (20 Days) 2,044,466
Income Statement In the last 12 months, Chinook Therapeutics had revenue of 6.13M
and earned -184.62M
in profits. Earnings per share was -2.87.
Revenue 6.13M Gross Profit 4.41M Operating Income -185.08M Net Income -184.62M EBITDA -164.2M EBIT -173.1M Earnings Per Share (EPS) -2.87
Full Income Statement Balance Sheet The company has 115.44M in cash and 39.44M in
debt, giving a net cash position of 76M.
Cash & Cash Equivalents 115.44M Total Debt 39.44M Net Cash 76M Retained Earnings -419.63M Total Assets 488.81M Working Capital 252.94M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -117.48M
and capital expenditures -1.65M, giving a free cash flow of -119.13M.
Operating Cash Flow -117.48M Capital Expenditures -1.65M Free Cash Flow -119.13M FCF Per Share -1.85
Full Cash Flow Statement Margins Gross margin is 71.9%, with operating and profit margins of -3020.28% and -3012.65%.
Gross Margin 71.9% Operating Margin -3020.28% Pretax Margin -2941.81% Profit Margin -3012.65% EBITDA Margin -2679.44% EBIT Margin -3020.28% FCF Margin -1944.09%
Dividends & Yields KDNY does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for KDNY.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Oct 2, 2020. It was a
backward
split with a ratio of 1:5.
Last Split Date Oct 2, 2020 Split Type backward Split Ratio 1:5
Scores Altman Z-Score 9.7 Piotroski F-Score 3
